# Diabetes Hub Monitor Review — 2026-06-22

**Run type:** Automated (scheduled, unattended)
**Scan reference:** hub_monitor.py 2026-06-22 07:06 · clinical trials + PubMed snapshots 2026-06-22 07:05–07:06
**Bottom line:** Quiet day. Zero clinical-trial deltas, normal PubMed churn, no new breaking news beyond what the corpus already captured. The one thing worth acting on is data staleness, not new findings — the literature gap *data* underneath the Jun-21 report is 63 days old (Apr 20), and 738 result files are >14 days old.

---

## File System Status

| Item | Status |
|------|--------|
| `clinical_trials_latest.json` | Fresh — 2026-06-22 07:05 (821 trials) |
| `pubmed_recent_latest.json` | Fresh — 2026-06-22 07:06 (172 papers, 30-day window) |
| `literature_gap_report.md` | 2026-06-21 08:07 (regenerated) |
| `literature_gap_data.json` | **STALE — 2026-04-20 (63 days).** Report was re-rendered but the underlying gap matrix was not recomputed |
| `hub_monitor_report.md` | Fresh — 2026-06-22 07:06 |
| All four expected script outputs present | Yes — no missing inputs |

Hub monitor flagged **738 result files older than 14 days**. Most are dated daily snapshots (expected archive growth), but the gap-analysis data file is the one stale item that actually feeds a live deliverable.

---

## Clinical Trial Changes

**Day-over-day diff (2026-06-21 → 2026-06-22): 0 new, 0 removed, 0 status changes, 0 new results posted.** No action required on trial movement.

Snapshot totals: 821 unique trials — 263 RECRUITING, 143 NOT_YET_RECRUITING, 300 COMPLETED-with-results, 124 PHASE3 (plus 15 PHASE2/3). Top sponsors unchanged: Eli Lilly (29), Novo Nordisk (27).

Key Phase 3 / late-stage trials being tracked (status stable, all aligned with Tier 1 watch areas) **[Certain — from latest snapshot]**:

| NCT | Sponsor | Therapy / Focus |
|-----|---------|-----------------|
| NCT04786262 / NCT06832410 | Vertex | VX-880 (zimislecel) islet cell therapy, T1D |
| NCT07222137 / NCT07222332 | Eli Lilly | Baricitinib — delay Stage 3 / preserve beta-cell function, T1D |
| NCT06914895 / NCT06962280 | Eli Lilly | Tirzepatide in T1D |
| NCT07088068 | Sanofi | Teplizumab head-to-head, T1D |
| NCT05018585 | Diamyd Medical | Diamyd (DIAGNODE-3), antigen-specific T1D prevention |
| NCT06334133 | vTv Therapeutics | Cadisegliatin (glucokinase activator) adjunct to insulin, T1D |

No Vertex/Lilly/Novo/Sana trial changed state since the last snapshot. **[Certain]**

---

## PubMed Highlights

Rolling 30-day window: 172 unique papers across 16 domains. Day-over-day: **15 new papers in, 15 aged out** — normal churn, no volume anomaly.

**Cross-domain papers (highest priority — appear in 2+ domains):**

- **PMID 42295172** — "In brief: An expanded indication for teplizumab (Tzield)." Domains: T1D Immunotherapy + key therapy teplizumab. Corresponds to the Jun-12 FDA pediatric approval (see Breaking News). **[Certain]**
- **PMID 42323169** — "'More Kairos, Less Chronos': Sleep, circadian rhythms and the path to cardiovascular, neurological [disease]." Domains: Diabetes AI/ML + Microbiome. Worth a skim — circadian × microbiome × AI is an unusual tri-domain hit.

**Key-therapy tracker:**

| Therapy | Paper hits (30d) | Note |
|---------|------------------|------|
| dapagliflozin | 44 | High — generic approvals driving volume |
| orforglipron | 9 | ACHIEVE-2 (vs dapagliflozin) & ACHIEVE-5 Phase 3 |
| retatrutide | 7 | Triple-agonist Phase 3 readouts (ADA 2026) |
| teplizumab | 7 | Expanded-indication coverage |
| icodec | 7 | Weekly insulin |
| CagriSema | 6 | REIMAGINE 1/2/3 Phase 3 series |
| baricitinib | 3 | Mostly non-diabetes (RA/COVID) — watch for signal contamination |
| **zimislecel** | **0** | Still no PubMed footprint despite active Vertex Phase 3 — tracker gap or naming mismatch worth checking |

**[Likely]** The zimislecel zero is a terminology artifact (literature still indexes it as VX-880), not an absence of activity. Verify the alert query covers both names.

---

## Gap Analysis Summary

Top 5 under-researched intersections (Gap Score, BRONZE validation — single analytic source, expert confirmation pending):

1. **Beta Cell Regen × Health Equity** — 100.0, 0 joint pubs
2. **Insulin Resistance × Islet Transplant** — 100.0, 1 joint pub
3. **Islet Transplant × Drug Repurposing** — 100.0, 0 joint pubs
4. **Islet Transplant × Health Equity** — 100.0, 0 joint pubs
5. **Gene Therapy × LADA** — 100.0, 0 joint pubs

**Alignment with Tier 1 contribution areas (RESEARCH_DOCTRINE.md):** Gaps #3, #8 (Glucokinase × Drug Repurposing), #12 and #13 all sit inside **Tier 1 #4 — Drug Repurposing Computational Screening (18/20)**. Islet Transplant × Drug Repurposing (#3) is the cleanest match: a defined target network, an open-data screening method, and a true zero-publication intersection. The gap exercise itself is **Tier 1 #2 — Literature Synthesis (19/20)**.

**Caveat that matters:** these scores are BRONZE and the data file is 63 days stale. Before treating any gap as real, it must be re-confirmed against a current PubMed query — a 100.0 score can equally mean "unexplored" or "terminology mismatch."

---

## Breaking News (web check, last ~7 days)

Nothing new in the strict 7-day window. The two genuinely significant items are ~10–16 days old and **already reflected in the corpus**, so no ingestion gap:

- **Tzield (teplizumab) — FDA accelerated approval for pediatric (ages 8–17) recently-diagnosed Stage 3 T1D, Jun 12, 2026.** First approved therapy for this indication; boxed warning for EBV/CMV reactivation. Captured as PMID 42295172. **[Certain]**
- **Retatrutide — first Phase 3 results in T2D + obesity, presented at ADA Scientific Sessions, Jun 6, 2026** (New Orleans). Triple GIP/GLP-1/glucagon agonist; benefit extended to OSA and knee OA pain. Captured in therapy tracker. **[Certain]**

No new FDA action, no new Phase 3 readout, no major retraction in the trailing week.

---

## Recommended Actions

1. **Re-run gap analysis — data is 63 days old.** `python project1_literature_gap_analysis.py` to regenerate `literature_gap_data.json`. The Jun-21 report was rendered off Apr-20 data; the report date is misleading.
2. **Fix the zimislecel alert query** — add "VX-880" as a synonym in `baseline_pubmed_alerts.py`; current zero hits almost certainly miss indexed literature.
3. **Review cross-domain paper PMID 42323169** (Sleep/circadian × AI/ML × Microbiome) — rare tri-domain hit, relevant to Tier 1 multi-omics.
4. **Pursue Islet Transplant × Drug Repurposing (Gap #3)** as the lead computational target — strongest Tier 1 fit, true zero-pub intersection, open-data method available. Confirm the gap with a live PubMed query first.
5. **No trial-tracker update needed today** — zero deltas. Notable-trials table in `clinical_trials_summary.md` is still empty; consider seeding it with the 6 watch trials listed above on the next attended session.

---

*Review-only run. No existing files modified. Gap classifications are BRONZE pending expert validation per Research Doctrine v1.0.*
